Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikhil Hebbar

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Cellular Physiology|May 4, 2012
Mechanisms of apoptosis by the tumor suppressor Par-4Nikhil Hebbar, Chi Wang, Vivek M Rangnekar
Cancer Cell|July 13, 2013
Par(-4)oxysm in breast cancerTripti Shrestha-Bhattarai, Nikhil Hebbar, Vivek M Rangnekar
Breast Cancer Research : BCR|October 30, 2013
Par-4 prevents breast cancer recurrenceNikhil Hebbar, Tripti Shrestha-Bhattarai, Vivek M Rangnekar
Advances in Experimental Medicine and Biology|July 9, 2014
Cancer-selective apoptosis by tumor suppressor par-4Nikhil Hebbar, Tripti Shrestha-Bhattarai, Vivek M Rangnekar
Cells|September 14, 2024
The Tumor Suppressor Par-4 Regulates Adipogenesis by Transcriptional Repression of PPARγJames Sledziona, Ravshan Burikhanov, Nathalia Araujo, et al.
Cell Reports|January 14, 2014
Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4Ravshan Burikhanov, Tripti Shrestha-Bhattarai, Nikhil Hebbar, et al.
Cancer Research|June 20, 2017
A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in TumorsNikhil Hebbar, Ravshan Burikhanov, Nidhi Shukla, et al.
Protein Engineering, Design & Selection : PEDS|November 12, 2019
Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancerKyungbo Kim, Pereira Araujo, Nikhil Hebbar, et al.
Cancer Research|December 4, 2012
Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4Ravshan Burikhanov, Tripti Shrestha-Bhattarai, Shirley Qiu, et al.
Haematologica|July 28, 2022
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulationAbishek Vaidya, Erin Doherty, Xiya Wu, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Cellular Physiology|May 4, 2012
Mechanisms of apoptosis by the tumor suppressor Par-4Nikhil Hebbar, Chi Wang, Vivek M Rangnekar
Cancer Cell|July 13, 2013
Par(-4)oxysm in breast cancerTripti Shrestha-Bhattarai, Nikhil Hebbar, Vivek M Rangnekar
Breast Cancer Research : BCR|October 30, 2013
Par-4 prevents breast cancer recurrenceNikhil Hebbar, Tripti Shrestha-Bhattarai, Vivek M Rangnekar
Advances in Experimental Medicine and Biology|July 9, 2014
Cancer-selective apoptosis by tumor suppressor par-4Nikhil Hebbar, Tripti Shrestha-Bhattarai, Vivek M Rangnekar
Cells|September 14, 2024
The Tumor Suppressor Par-4 Regulates Adipogenesis by Transcriptional Repression of PPARγJames Sledziona, Ravshan Burikhanov, Nathalia Araujo, et al.
Cell Reports|January 14, 2014
Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4Ravshan Burikhanov, Tripti Shrestha-Bhattarai, Nikhil Hebbar, et al.
Cancer Research|June 20, 2017
A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in TumorsNikhil Hebbar, Ravshan Burikhanov, Nidhi Shukla, et al.
Protein Engineering, Design & Selection : PEDS|November 12, 2019
Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancerKyungbo Kim, Pereira Araujo, Nikhil Hebbar, et al.
Cancer Research|December 4, 2012
Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4Ravshan Burikhanov, Tripti Shrestha-Bhattarai, Shirley Qiu, et al.
Haematologica|July 28, 2022
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulationAbishek Vaidya, Erin Doherty, Xiya Wu, et al.
Pageof 2